Sign in
Stories
Acquisition Progress Amid Safety Concern
Share
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
ADOCIA Files 2023 Registration Document
AEON Biopharma Advances Migraine Treatme...
AEON Biopharma Advances Migraine Treatme...
Overview
API
Morphosys reassures investors amidst safety concern over its drug pelabresib as the Novartis acquisition remains unaffected.
Ask a question
Could this incident affect the overall perception of biotechnological advancements and investments?
How might the safety concern impact the future development of pelabresib?
What strategies could Morphosys employ to address investor concerns effectively?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage